Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04127110
Title Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients (ALKALINE)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors European Organisation for Research and Treatment of Cancer - EORTC
Indications

lung non-small cell carcinoma

Therapies

Lorlatinib

Age Groups: adult | senior
Covered Countries

Additional content available in CKB BOOST